Influence of ethnicity on pharmacogenetic variation in the ghanaian population

Pharmacogenomics Journal

Volumn 9, Issue 6, 2009, Pages 373-379

  Yen Revollo, J L ^a,d   Van Booven, D J ^b,d   Peters, E J ^a,e   Hoskins, J M ^a,d   Engen, R M ^b,d,f   Kannall, H D ^b,g   Ofori Adjei, D ^c   McLeod, H L ^a,d   Marsh, S ^b,d,h  

^a University of North Carolina   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GHANA   (Ghana)

^d Pharmacogenetics for Every Nation Initiative (PGENI)   (United States)

^e ILLUMINA INC   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g MONSANTO COMPANY   (United States)

^h Pharmacogenomics Centre   (Canada)

Author keywords

Ethnic group; Ghana; Pharmacogenetics; Polymorphism; Population

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIHYDROPYRIMIDINE DEHYDROGENASE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GHANA; HUMAN; MALE; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; GHANA; HUMANS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; UNITED STATES;

EID: 73949122677     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.28     Document Type: Article

References (33)

1. Marsh S, Van Booven DJ, McLeod HL. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 2006; 7: 625-631.
2. Marsh S. Pharmacogenetics: global clinical markers. Pharmacogenomics 2008; 9: 371-373.
3. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P450 3A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121-132.
4. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367-370.
5. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
6. Engen R, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Current Drug Targets 2006; 7: 1641-1648.
7. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861.
8. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-1248.
9. Dandara C, Sayi J, Masimirembwa CM, Magimba A, Kaaya S, De Sommers K et al. Genetic polymorphism of cytochrome P450 1A1 (CYP1A1) and glutathione transferases (M1, T1 and P1) among Africans. Clin Chem Lab Med 2002; 40: 952-957.
10. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M et al. Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. Int J Cancer 2000; 86: 1-7.
11. Jorde LB, Wooding SP. Genetic variation, classification, and 'race'. Nat Genet 2004; 36(11 Suppl): S28-S33.
12. Yu N, Chen FC, Ota S, Jorde LB, Pamilo P, Patthy L et al. Larger genetic differences within Africans than between Africans and Eurasians. Genetics 2002; 161: 269-274.
13. Owen R. Important variant information for VKORC1 2007. www.pharmgkb.org.
14. Yuan H-Y, Chen J-J, Lee MTM, Wung J-C, Chen Y-F, Charng M-J et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
15. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006; 80: 169-178.
16. World Health Organization. WHO model list of essential medicines 2007 15th list. www.who.int/medicines/publications/08-ENGLISH-indexFI-NAL-EML15.pdf.
17. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003; 13: 19-28
18. Pharmaco Genetics for Every Nation Initiative. www.pgeni.org, 2008.
19. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R et al. Distribution and concordance of N-acetyltrans-ferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999; 8: 683-692.
20. Shi Q, Zhang Z, Neumann AS, Li G, Spitz MR, Wei Q. Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. Carcinogenesis 2005; 26: 649-656. (Pubitemid 41214156)
21. Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12: 725-733.
22. Flori L, Delahaye NF, Iraqi FA, Hernandez-Valladares M, Fumoux F, Rihet P. TNF as a malaria candidate gene: polymorphism-screening and family-based association analysis of mild malaria attack and parasitemia in Burkina Faso. Genes Immun 2005; 6: 472-480.
23. Mombo LE, Ntoumi F, Bisseye C, Ossari S, Lu CY, Nagel RL et al. Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. Am J Trop Med Hyg 2003; 68: 186-190.
24. Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 2008; 27: 21.
25. Al-Yahyaee S, Gaffar U, Al-Ameri MM, Qureshi M, Zadjali F, Ali BH et al. N-acetyltransferase polymorphism among northern Sudanese. Hum Biol 2007; 79: 445-452.
26. Dandara C, Masimirembwa CM, Magimba A, Kaaya S, Sayi J, Sommers DK et al. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C4T and 590G4A. Pharmacogenetics 2003; 13: 55-58.
27. Gara S, Abdennebi M, Chatti S, Touati S, Ladgham A, Guemira F. Association of NAT2 gene substitution mutation T341C with increased risk for head and neck cancer in Tunisia. Acta Oncol 2007; 46: 834-837
28. The International HapMap Project 2008. www.hapmap.org.
29. Marsh S, King CR, Garsa AA, McLeod HL. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 2005; 311: 97-114.
30. McGuire W, Knight JC, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis 1999; 179: 287-290.
31. Moukoko CE, El Wali N, Saeed OK, Mohamed-Ali Q, Gaudert J, Adessein AJ et al. No evidence for a major effect of tumor necrosis factor alpha gene polymorphisms in periportal fibrosis caused by Schistosoma mansoni infection. Infect Immun 2003; 71: 5456-5460.
32. Corbett EL, Mozzato-Chamay N, Butterworth AE, De Cock KM, Williams BG, Churchyard GJ et al. Polymorphisms in the tumor necrosis factor-alpha gene promoter may predispose to severe silicosis in black South African miners. Am J Respir Crit Care Med 2002; 165: 690-693.
33. McCanlies EC, Schuler CR, Kreiss K, Frye BL, Ensey JS, Weston A. TNF-alpha polymorphisms in chronic beryllium disease and beryllium sensitization. J Occup Environ Med 2007; 49: 446-452.